Navigation Links
Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
Date:3/13/2013

NEW YORK, March 13, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), St. Jude Medical, Inc. (NYSE: STJ), Cardiovascular Systems Inc (NASDAQ: CSII) and MAKO Surgical Corp. (NASDAQ: MAKO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

Abbott Laboratories has released new data indicating that Abott's Absorb Bioresorbable Vascular helps improve blood vessel movement in patients with coronary heart disease (CAD). Absorb is the first of its kind device that works by opening clogged vessels and restoring blood flow. Unlike metallic stents, Absorb dissolve over time, potentially allowing natural blood flow to return. Absorb is already commercially available in Europe and other international market, but is still an investigational device in the United States. Separately, Abbott announced data from the EVEREST II study, showing that Abbott's MitraClip System may help treat patients who are not allowed to go through mitral valve surgery due to risk of mortality. With these products, Abbott is well-positioned to capitalize on the United States' vascular market. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/9cb0_ABT]

--

Stryker Corporation Research Report

Stryker recently completed its acquisition of Trauson Holdings Company Limited, a manufacturer of trauma-related products in China. This acquisition is a critical step in helping Stryker broadens its presence in the region, though the financial benefits of this acquisition is not expected to impact Stryker's earnings for 2013. Due to this acquisition, Goldman Sachs reiterated its Buy rating on Stryker Corporation and promptly increased its price target from $71 to $72. Goldman Sachs notes that this acquisition could be accretive for Stryker in the long-term, especially if Stryker "proves successful at leveraging Trauson's existing channels in China to sell a broader product range." Stryker's deepened presence in emerging markets helps position it for future growth. The Full Research Report on Stryker Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8335_SYK]

--

St. Jude Medical, Inc. Research Report

St. Jude Medical makes its way to Japan by launching its ILUMIEN OPTIS System in the region. The product is used to help physicians make personalized stenting decisions based on each patient's unique anatomy and disease state. According to William Phillips , president of St. Jude Medical Japan, the company is excited about expanding its reach of the ILUMIEN OPTIS in Japan, a world leader in imaging technology. In Japan, around 245,000 Percutaneous Coronary Intervention (PCI) procedures are performed to treat cardiovascular disease, and 80 percent are said to use the technology, showing the potential market for ILUMIEN OPTIS. Aside from this, St. Jude Medical's AMPLATZER Cardiac Plug, a product for the prevention of stroke, is said to be on track with its development, showing continued strength in the company's atrial fibrillation business. These latest developments are in line with the company's commitment to deliver strong EPS growth without sacrificing investment for its pipeline. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d3fb_STJ]

--

Cardiovascular Systems Inc Research Report

Cardiovascular Systems made headlines after the company presented results from its ORBIT II study of severely calcified coronary lesions. The results showed that CSI's orbital atherectomy technology may be a viable treatment option for patients with severe calcified lesions. The results showed study endpoints were met by a significant margin. These results make the prospects of the company's coronary business seem brighter, helping it move forward towards its goal of filing the product for FDA approval. The company believes that the market opportunity for this technology is estimated to exceed $1.5 billion annually in the US alone. Shares of Cardiovascular Systems jumped 16.55 percent following the release of these results. The Full Research Report on Cardiovascular Systems Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8bf1_CSII]

--

MAKO Surgical Corp. Research Report

MAKO has been steadily gaining after the robotic arm and orthopedic implants manufacturer reported impressive fourth quarter and full year 2012 results. Its revenue for the year totaled at $102.7 million, showing an increase of 22 percent over 2011. This increase was due to stronger sales of RIO systems and higher MAKOplasty procedure volumes. At present, the company is currently training physicians to perform its procedures to increase the volume of MAKOplasty procedures, drive sales of its RIO systems, and increase profitability. The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/1687_MAKO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826


'/>"/>
SOURCE Investors-Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MDHI Receives Strategic Investment to Continue Strong Growth - Moves into Positive Operating Cash Flow for March 2013 Quarter
2. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
3. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
4. Soterix Medical Inc. reports positive results from High-Definition tDCS Fibromyalgia Trial at Harvard Medical School
5. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
6. IMD Companies, Inc. (ICBU) Announces Procedure for Issuance of Positive Solutions Stock
7. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
8. IDEV gibt Ergebnisse von Studie zur Revaskularisation mit Supera an echten Patienten (RESTORE) bekannt - Studie demonstriert positive klinische Ergebnisse bei schwerkranken Patienten mit langen Läsionen
9. Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug
10. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
11. MDHI to Hold Conference Call Thursday, Jan 31st to Discuss Business Growth and Positive Cash Flow - Releases Additional Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):